Airway Disease in 2026: Precision Medicine Meets Environmental and Clinical Reality

The 2025-2026 conference season in respiratory and allergy medicine has surfaced signals that the field is shifting faster than many clinical systems can absorb. The agendas converge on themes that were peripheral a decade ago: precision phenotyping, remission as a treatment target, the united airway as a clinical organizing principle, metabolic-inflammatory crossover, and the environmental forces reshaping disease burden in real time. This article traces those signals through emerging conference data, updated guidelines from GINA and ARIA-EAACI, and the growing evidence that climate-driven pollen shifts and access disparities are widening the gap between what the science now offers and what patients receive. It extends the analysis to environmental burden, emerging therapeutic signals, and translational challenges that define airway disease, with attention to the engineering infrastructure, including health digital twins and cross-specialty decision support, needed to close the gap between scientific capability and patient care.